perpetuity. preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in medRxiv preprint doi: [https://doi.org/10.1101/2024.11.05.24316768;](https://doi.org/10.1101/2024.11.05.24316768) this version posted November 7, 2024. The copyright holder for this

All rights reserved. No reuse allowed without permission.

**RESEARCH ARTICLE** *Submitted to Magnetic Resonance in Medicine*

# **An Optimal Mass Transport Model for the Analysis of DCE-MRI and its Application to Breast Cancer Treatment Response**

Xinan Chen<sup>1</sup><sup>O</sup> | Wei Huang<sup>2,3</sup> | Amita Shukla-Dave<sup>1,4</sup> | Ramesh Paudyal<sup>1</sup> | Roberto Lo Gullo<sup>4,5</sup> | Marcelina Perez<sup>4</sup> | Katja Pinker<sup>4,5</sup> | Joseph O. Deasy<sup>1</sup>

<sup>1</sup>Department of Medical Physics, Memorial Sloan Kettering Cancer Center, New York, USA

01

07 08

23

31 32

37

45

47 48

51

- <sup>2</sup>Advanced Imaging Research Center, Oregon Health & Science University, Oregon, USA
- <sup>3</sup>Department of Radiation Oncology, Corewell Health William Beaumont
- University Hospital, Michigan, USA <sup>4</sup>Department of Radiology, Memorial Sloan Kettering Cancer Center, New
- York, USA <sup>5</sup>Department of Radiology, Columbia
- University, New York, USA
- <sup>6</sup>Departments of Computer Science and Applied Mathematics & Statistics, Stony Brook University, New York, USA

#### **Correspondence**

Xinan Chen, Ph.D., Department of Medical Physics, Memorial Sloan Kettering Cancer Center, New York, USA. Email: chenx7@mskcc.org

#### **Funding Information**

This study was supported by the NIH Cancer Center Support grant to MSK (P30 CA008748), NIH grant U01 CA154602, R01 CA248192, The Enid A. Haupt Endowed Chair Fund for Medical Physics, The Simons Foundation, and a Breast Cancer Research Foundation grant (BCRF-17-193).

#### **Abstract**

**Purpose:** Dynamic contrast-enhanced MR imaging (DCE-MRI) is widely deployed in cancer care and research, but the methods conventionally used to quantify contrast agent kinetics do not account the cross-voxel movement characterized by advection and diffusion. We hypothesized that unbalanced optimal mass transport could be used to quantify and visualize such contrast agent flows across tumor volumes.

**Methods:** We developed a computational fluid dynamics model termed the unbalanced regularized optimal mass transport (urOMT) model. We tested the urOMT on a multi-institutional dataset of 153 longitudinal DCE-MRI scans from 39 breast cancer patients treated with neoadjuvant chemotherapy (NACT.)

**Results:** The urOMT model can quantify dynamic fluid transport properties such as net speed, flux and rates of contrast entering and leaving the tumor (influx and efflux). The urOMT model can also visualize the trajectories and directions of net fluid flows. Quantitative metrics from urOMT exhibited distinct patterns that may be relevant to predicting pathological complete response (pCR) to NACT.

**Conclusion:** The urOMT model can be used to estimate and visualize local fluid flow in DCE-MRI breast cancer images. Model-based estimates of flux, influx and efflux should be tested as potential predictive imaging biomarkers to measure treatment effectiveness in patients treated with NACT. The urOMT model in principle has applicability to other cancer imaging use cases, but this will require further testing.

#### **KEYWORDS:**

optimal transport, fluid dynamics, DCE-MRI, breast cancer

perpetuity. preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in medRxiv preprint doi: [https://doi.org/10.1101/2024.11.05.24316768;](https://doi.org/10.1101/2024.11.05.24316768) this version posted November 7, 2024. The copyright holder for this

Received Day Month Year; | Revised Day Month Year; | All rights reserved. No reuse allowed without permission.<br>Received Day Month Year: | Revised Day Month Year; | Accepted Day Month Year

## $\mathbf{D}^{\mathrm{DOL:~xxx/xxx}}$  INTRODUCTION

01

04

51 52 53 Locally advanced breast cancer is often treated with neoadjuvant chemotherapy (NACT), aiming for the reduction of tumor size prior to definitive surgery.  $1,2$  $1,2$ However, patient response to NACT is highly variable. [3](#page-11-2)[,4](#page-11-3) Improved imaging methods that yield clinically useful prognostic information and effectively predict treatment response could potentially be used to adapt individualized treatment courses.

T1-weighted dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI) has become a widely used imaging technique in many areas of cancer care and research, including breast cancer.<sup>[5](#page-11-4)[,6,](#page-11-5)[7](#page-11-6)[,8](#page-11-7)[,9](#page-11-8)</sup> In DCE-MRI data acquisition, a chemically inert gadolinium-based contrast agent is usually injected intravenously into the patient. Before, during, and after the contrast administration, a series of MR images are acquired to identify the uptake and washout patterns exhibited by contrast agent for assessment of contrast kinetics.<sup> $7,8$  $7,8$ </sup> Tumors generally demonstrate faster uptake and washout of the contrast agent compared to normal tissues, but in a spatially heterogenous pattern. [10](#page-11-9)

The term *advection* broadly refers to the net transport of directional bulk flows of a quantity, and can be mathematically characterized with a continuous velocity vector field with a local magnitude and direction. In the human body, advection is primarily driven by a gradient of pressure to enable the transport of fluids and gases essential for normal physiological functions. Distinct from advection, *diffusion* is directionless transport due to a gradient of concentration, and can be quantitatively described by the Fick's law. During a DCE-MRI experiment, the contrast agent first arrives at the tumor within blood vessels, often entering increasingly smaller and disorganized capillaries in the tumor. Contrast agent extravasates blood vessels passively, a process called *influx*, thereupon entering the extravascular-extracellular tissue space. Contrast agent flow within the tissue space is non-advective and mainly via directionless diffusion. Eventually, the contrast agent passively exits the extravascular-extracellular space through a process called *efflux*, with some portion reabsorbed back to the blood vessels and the rest drained via lymphatic vessels.  $^{11,12,13,14}$  $^{11,12,13,14}$  $^{11,12,13,14}$  $^{11,12,13,14}$  $^{11,12,13,14}$  $^{11,12,13,14}$  Figure [1](#page-2-0) shows a schematic of the aforementioned process. Advection mainly captures the net in-vessel bulk flows, which are microscopically varied, whereas diffusion captures the uncorrelated flow component in the interstitial space of the tissue. 24 25 26 27 28 29 31 37 38 39 40 41 42 43 45 47 48 49 50

The DCE-MR images can be analyzed with semiquantitative (SQ) methods, which evaluate signal

changes over time,  $15$  or quantitative methods, which  $54$ perform pharmacokinetic (PK) modeling of tissue contrast concentration time-course data converted from 56 signal time-course data.  $^{16,17,18,19}$  $^{16,17,18,19}$  $^{16,17,18,19}$  $^{16,17,18,19}$  $^{16,17,18,19}$  $^{16,17,18,19}$  The latter require high  $^{57}$ temporal resolution of the time-course data and quantifi-58 cation of the arterial input function. [20](#page-12-9) Previous studies 59 reported that the SQ and PK methods (e.g., extended 60 Tofts model (ETM) and shutter speed model) exhibited 61 potential for early prediction of breast cancer response 62 to NACT by capturing the longitudinal changes of tumor 63 contrast agent kinetics in response to NACT. [21](#page-12-10)[,22](#page-12-11)[,23,](#page-12-12)[24](#page-12-13) 55 64

However, ETM<sup>[25,](#page-12-14)[26](#page-12-15)</sup> models only consider the direct  $65$ exchange of contrast agent molecules between the ves-  $66$ sels (considered one global reservoir) and the local 67 interstitial tumor tissue in a given image voxel, but com-68 pletely ignore any cross-voxel transport throughout the <sup>69</sup> microvasculature and tissue characterized by advection 70 and diffusion. Consequently, the transport of contrast 71 agent within a tumor is not explicitly considered or mod-72 eled, and there is a great interest and unmet need to 73 develop a new state-of-the-art model for the analysis of 74 DCE data that includes the transport effects of advection 75 and diffusion.

Our approach to address this problem is to apply 77 optimal mass transport (OMT) theory to DCE-MRI 78 data to track the cross-voxel flows in the tumor microen-79 vironment. The OMT problem is concerned with finding 80 the best transport plan from one initial mass distribu-81 tion to another in the sense of minimized transportation  $82$ cost. [27,](#page-12-16)[28,](#page-12-17)[29](#page-12-18) In the formulation of Benamou and Bre-83 nier,  $^{29}$  $^{29}$  $^{29}$  the OMT problem was, for the first time, framed  $^{84}$ in a fluid dynamics setting where the classic conti-85 nuity equation is employed to describe the advective  $86$ movement of fluid flows. A regularized version of the  $\frac{87}{6}$ OMT model was later proposed  $30,31,32,33$  $30,31,32,33$  $30,31,32,33$  $30,31,32,33$  and has been  $88$ widely applied in numerous research areas, including  $89$ machine learning and deep learning  $34,35,36,37$  $34,35,36,37$  $34,35,36,37$  $34,35,36,37$  but also  $90$ in molecular biology.  $38,39$  $38,39$  From the point of view of  $91$ fluid dynamics, this regularization term can be equivalently treated as a diffusion term of a given quantity. In  $93$ our previous work, we developed a regularized version 94 of the optimal mass transport model (denoted rOMT) 95 in computational fluid dynamics which employed an 96 advection-diffusion equation to quantify and visualize 97 glymphatic fluid behaviors in rat brains studied with 98 DCE-MRI.  $40,41,42,43,44,45$  $40,41,42,43,44,45$  $40,41,42,43,44,45$  $40,41,42,43,44,45$  $40,41,42,43,44,45$  $40,41,42,43,44,45$  In order to further extend the 99 validity of the model when contrast enters and leaves  $100$ the imaged volume, we added a source term into the 101 rOMT model to allow for unbalanced mass gain and loss,  $102$ resulting in the unbalanced regularized OMT (urOMT) 103 model.<sup>[46](#page-13-4)</sup> The unbalanced version of OMT has been 104 studied in other applications  $47,48,49$  $47,48,49$  $47,48,49$  including image processing  $50,51$  $50,51$ , neuroscience  $46$ , and cell biology.  $52,53$  $52,53$ 105 106 AUTHOR ONE ET AL **3**<br>All rights reserved. No reuse allowed without permission. perpetuity. preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in medRxiv preprint doi: [https://doi.org/10.1101/2024.11.05.24316768;](https://doi.org/10.1101/2024.11.05.24316768) this version posted November 7, 2024. The copyright holder for this

37 38

45

47

49

51

53

<span id="page-2-0"></span>

**FIGURE 1** Schematic of the transport flows of the contrast agent after being intravenously administrated. Contrast agent molecules are delivered to the tumor via relatively large blood vessels which feed disorganized arterial microvasculature. Blood and contrast agent are passively transported into interstitial extracellular tissue regions in a process referred to as influx. Directionless diffusion of the contrast agent can occur in the extravascular-extracellular space, but is limited in range. The interstitial contrast agent is removed both through venous blood vessels or into the lymphatic drainage system (efflux). Individual contrast molecules may exit and enter the vascular system multiple times.

As continuing work of [\[46,](#page-13-4) [54,](#page-13-12) [55\]](#page-13-13), here we employed the urOMT model, of which the numerical method was developed and detailed in Chen et al., [\[46\]](#page-13-4) to analyze breast cancer DCE-MRI data. In the urOMT model, fluid behavior is governed by a fluid dynamic partial differential equation:

$$
\frac{\partial \rho}{\partial t} + \nabla \cdot (\rho v) = \sigma \Delta \rho + \rho r \tag{1}
$$

where  $\rho = \rho(t, x)$  is the concentration of a given quantity,  $v = v(t, x)$  is the velocity field of the quantity,  $\sigma$ is the constant diffusion coefficient of the quantity, and  $r = r(t, x)$  is called the source variable which quantifies the rate of mass gain (when  $r > 0$ ) or loss (when  $r < 0$ ) of the quantify. Optimal mass transport seeks to minimize an objective function while respecting the boundary conditions and the fluid dynamic equation. The urOMT algorithm solves for the optimal *v* and *r* which, under the context of cancer microenvironment measured by DCE-MRI, are the net velocity field and the rate of local influx or efflux rates of the injected contrast agent, respectively.

In this study, we applied the urOMT model to longitudinal DCE-MRI data sets obtained from breast cancer patients treated with NACT to quantify and visualize the fluid behaviors of the tumor microenvironment. The derived fluid dynamics metrics over the course of treatment were compared to outcomes of pathologic response as potential biomarkers of therapeutic response.

#### 2 | METHODS

### **2.1 DCE-MRI Data Acquisition and Pre-Processing**

55

58

 $65$ 

70

80 81

104 105 106

To investigate the applicability of urOMT to breast cancer treatment response, we analyzed a total of 153 longitudinal DCE-MRI data sets from 39 breast cancer patients treated with NACT. The data were obtained from a prospective single-center IRB-approved clinical study. [56](#page-13-14) Most patients were consented to undergo four DCE-MRI scans: before NACT (baseline visit 1, denoted V1), after the first cycle of NACT (V2), at the mid-point of NACT (V3, usually after three or four NACT cycles) and after the completion of NACT but before surgery (V4). For DCE-MRI data acquisition, 28-32 frames of axial volumetric images with bilateral full breast coverage were acquired over a scan time lasting ∼10 minutes. See Ref. [\[56\]](#page-13-14) for more details on DCE-MRI acquisition. 83 84 85 86 87 88 89 90 91 92 94 96

Standard of care pathological analysis of tumor specimens from surgery classifies NACT response outcome as either pathologic complete response (pCR, 8 patients) or non-pCR (31 patients). Here, a pCR is defined as the absence of residual tumor. Figure [2](#page-3-0) displays the DCE-MRI images of one pCR patient and one non-pCR patient across four MRI visits. 97 98 103

<span id="page-3-0"></span>

**FIGURE 2** Cropped breast DCE-MRI image slice through the center of the tumor from a pCR patient (top row) and a non-pCR patient (bottom row) across 4 MRI visits, V1, V2, V3 and V4. The contrast-enhanced tumors are clearly visible for both patients at V1.

For each DCE-MRI study, the tumor contour (i.e., the tumor region of interest, ROI) was manually segmented out by fellowship trained dedicated breast radiologists with 1 and 9 years of experience on post-contrast images using [3D Slicer.](https://www.slicer.org) [57](#page-13-15)

## **2.2 The urOMT Model**

In this section, we describe the formal mathematical definition of the urOMT model and the corresponding numerical method developed for applications in 3D DCE-MRI images. [40,](#page-12-29)[42,](#page-13-0)[46](#page-13-4)

#### $2.2.1$  Mathematical Formulation

The urOMT model used in this work can be formulated as follows. Given an initial mass density distribution  $\rho_0(x) \geq 0$  and a final one  $\rho_1(x) \geq 0$  defined on a bounded region  $\Omega \subseteq \mathbb{R}^3$ , one seeks to solve the following optimization problem

<span id="page-3-3"></span>
$$
\min_{\rho, v, r} \quad \int\limits_{0}^{T} \int\limits_{\Omega} \rho(t, x) (\|v(t, x)\|^2 \quad \text{(2a)}
$$
\n
$$
+ \alpha r^2(t, x) \, \mathrm{d}x \, \mathrm{d}t
$$

subject to  $\frac{\partial \rho}{\partial t} + \nabla \cdot (\rho v) = \sigma \Delta \rho + \rho r,$  (2b)

48 49

51 52 53

$$
\rho(0, x) = \rho_0(x), \quad \rho(T, x) = \rho_1(x) \quad (2c)
$$

where  $\rho(t, x) : [0, T] \times \Omega \to \mathbb{R}^+$  is the time-dependent mass density function;  $v(t,x) : [0,T] \times \Omega \to \mathbb{R}^3$  is a net time-dependent velocity field which indicates the direction and magnitude of the advective transport;

and  $r(t, x)$  is the time-dependent relative-source variable which controls the relative rate of instantaneous mass gain and loss (influx and efflux rates in the context of tumor microenvironment). The parameter  $\alpha > 0$   $\frac{77}{20}$ is the weighting parameter of the source term in the cost 78 function [\(2a\)](#page-3-1), and the parameter  $\sigma > 0$  is the isotropic  $\tau_9$ constant diffusion coefficient which allows the mass to be  $80$ passively dispersed along its spatial gradient according to Fick's law. 74 81

The equation  $(2b)$  is an unbalanced version of the  $\frac{83}{2}$ usual advection-diffusion equation in fluid dynamics. In 84 the language of transport phenomena, equation  $(2b)$  can  $85$ be rewritten as 86

$$
\frac{\partial \rho}{\partial t} + \nabla \cdot (J_A + J_D) = s \tag{3}
$$

8

<span id="page-3-4"></span><span id="page-3-2"></span><span id="page-3-1"></span>where  $J_A = \rho v$  is the advective flux and  $J_D = -\sigma \nabla \rho_{89}$ is the diffusive flux describing the magnitude and direction of advective and diffusive transport, respectively;  $\frac{91}{2}$ and  $s = \rho r$  is the source describing the amount of entry  $\frac{92}{2}$ (when  $s > 0$ ) or the exit (when  $s < 0$ ) of the given quantity into or out of the system per unit time. Note that 94  $J_A$  and  $J_D$  do not change the total amount of mass of  $\frac{95}{20}$ the quantity in the entire process because advection and  $_{96}$ diffusion are both subject to the mass conservation law.  $\frac{97}{6}$ Thus, we call  $\nabla \cdot (J_A + J_D)$  the *balanced* components <sub>98</sub> of transport. On the contrary,  $s = \rho r$  does contribute  $\frac{99}{2}$ to the variation of the local and global mass (of the  $_{100}$ contrast agent in the tumor) and consequently we refer  $_{101}$ to it as the *unbalanced* component of the transport. 102 The first term in the cost function  $(2a)$  is analogous to  $103$ the total kinetic energy of the transport process within the tumor. In contrast, the second term is denoted the 105

106

70

Fisher-Rao term and can be said to relate to the information geometry.  $58$  The urOMT problem [\(2\)](#page-3-3) thus solves for the optimal transport strategy as measured by  $\rho, v$ and *r* which together transform  $\rho_0$  into  $\rho_1$  via the transport equation [\(2b\)](#page-3-2), subject to a minimized cost function  $(2a)$ .

01

07 08

21

23

27

31

34

38 39 40

42

45

47 48 49

51

53

In the context of the tumor microenvironment measured by DCE-MRI, the concentration of the injected contrast agent, calculated with known longitudinal relaxivity from the DCE-MRI signal intensity, is modeled by the mass density  $\rho$  in the urOMT formulation [\(2\)](#page-3-3). The velocity field *v* delineates the advective behavior (i.e., the net microvascular and lymphatic flow) in the analyzed region. As noted above, diffusion is characterized with a constant coefficient. Advection and diffusion together account for the cross-voxel exchange of the contrast agent. The relative-source *r* represents the relative rate of influx when  $r > 0$  and efflux when  $r < 0$ . In summary, the urOMT model incorporates four types of transport: entry (influx) and exit (efflux) into and out of the tumor tissue volume, bulk advective flow within vessels and lymphatics, and localized diffusive flow that is extravascular and extracellular.

#### 2.2.2 | Numerical Method

We first converted the DCE-MRI signal intensity into the concentration of the injected contrast agent, using the following equations for spoiled gradient recalled echo sequence (with minimum TE) and a linear relationship between longitudinal relaxation rate  $(R_1 = 1/T_1)$ constant and contrast agent concentration under fast exchange limit approximation: [59](#page-13-17)

$$
S_{relative}(t) = \frac{S(t)}{S_0}
$$
\n(4a)

$$
B = \frac{1 - \exp(-\frac{TR}{T_{10}})}{1 - \exp(-\frac{TR}{T_{10}})\cos\theta}
$$
(4b)

$$
\frac{1}{T_1(t)} = \frac{1}{TR} \log \left( \frac{1 - BS_{relative}(t) \cos \theta}{1 - BS_{relative}(t)} \right) \tag{4c}
$$

$$
C(t) = \frac{1}{r_1} \left( \frac{1}{T_1(t)} - \frac{1}{T_{10}} \right)
$$
\n(4d)

where  $S(t)$  is the MRI signal at time *t*;  $S_0$  is the baseline signal before administration of contrast agent; *T R* is the repetition time; T1 (t) is the longitudinal relaxation time constant at time t;  $T_{10}$  is the pre-contrast longitudinal relaxation time constant;  $\theta$  is the flip angle;  $r_1$  is the longitudinal relaxivity of the contrast agent;  $C(t)$  is the concentration of contrast agent at time *t*.

 $C(t)$  is therefore represented by the mass density  $\rho(t, x)$  in the urOMT formulation [\(2\)](#page-3-3). In order to

deal with noise in the images, we first apply an edgepreserving filter to moderately smooth out image noise. In addition, in the numerical implementation, we solve the problem  $(2)$  with a free end point condition. Specifically, rather than a fixed end point condition in equations 58 [\(2c\)](#page-3-4) that  $\rho(T,x) = \rho_1(x)$ , we move this condition to  $\frac{59}{5}$ the cost function to be minimized. The purpose is to  $\frac{60}{2}$ avoid forcing the algorithm to match the noisy end- $61$ point exactly. Instead, this approach matches the end 62 point image approximately. Consequently, the numerical 63 formulation can be written as follows. 55 56 64

With two given 3D images,  $\rho_0^{img}(x)$  and  $\rho_1^{img}(x)$ , one 65 solves

+ *αr*<sup>2</sup>

<span id="page-4-0"></span>
$$
\min_{v,r} \int\limits_{0}^{T} \int\limits_{\Omega} \rho(t,x) \big( \left\| v(t,x) \right\|^2 \qquad \qquad \text{(5a)} \quad \text{\tiny{68}} \\
$$

<span id="page-4-3"></span>
$$
-\alpha r^2(t,x)\bigr)\,\mathrm{d} x\,\mathrm{d} t\qquad \qquad ^{70}
$$

$$
+\beta\int\limits_{\Omega}(\rho(T,x)-\rho_{1}^{img}(x))^{2}\,\mathrm{d}x
$$

subject to 
$$
\frac{\partial \rho}{\partial t} + \nabla \cdot (\rho v) = \sigma \Delta \rho + \rho r, \qquad (5b)_{75}
$$

$$
\rho(0, x) = \rho_0^{img}(x) \tag{5c}
$$

where  $\beta > 0$  is the weighting parameter for the fitting term in the cost function. 77 78

Here we briefly outline the numerical solution scheme used. One can find more details in Ref. [\[46\]](#page-13-4). Note that a bold font is used to denote discretized flattened vectors. For the numerical discretization, the cubic region  $\Omega$  is divided into a cell-centered grid of size  $n_1 \times n_2 \times n_3$  with uniform length  $\Delta x$ ,  $\Delta y$  and  $\Delta z$ , and then  $n = n_1 n_2 n_3$ is the total number of voxels. The time interval [0*, T*] is discretized into *m* equal intervals of length  $\Delta t = T/m$ . We set  $t_i = i \cdot \Delta t$  for  $i = 0, \dots, m$ . Set  $\boldsymbol{\rho} = [\boldsymbol{\rho_1}; \dots; \boldsymbol{\rho_m}]$ ,  $\rho_0 = \rho_0^{img}, v = [v_0; \cdots; v_{m-1}], r = [r_0; \cdots; r_{m-1}]$  where each  $\rho_i$  denotes the intensity at  $t = t_i$  and each pair of  $v_i$  and  $r_i$  denotes the velocity field and relative-source transforming  $\rho_i$  to  $\rho_{i+1}$ . 80 81 82 83 84 85 86 87 88 89 90 91

<span id="page-4-6"></span><span id="page-4-5"></span><span id="page-4-4"></span>The discrete version of the problem [\(5\)](#page-4-0) is therefore

$$
(\Delta t \Delta x \Delta y \Delta z) \rho^{T} (I_{m} \otimes [I_{n}, I_{n}, I_{n}]) (\boldsymbol{v} \odot \boldsymbol{v})
$$
  
\n
$$
\min_{\boldsymbol{v}, \boldsymbol{r}} + \alpha (\Delta t \Delta x \Delta y \Delta z) \rho^{T} (\boldsymbol{r} \odot \boldsymbol{r})
$$
  
\n
$$
+ \beta (\Delta x \Delta y \Delta z) \|\boldsymbol{\rho}_{\boldsymbol{m}} - \boldsymbol{\rho}_{\boldsymbol{1}}^{\text{img}} \|^{2}
$$
  
\n(6a)

subject to  $\rho_{i+1} = L^{-1}S(v_i)R(r_i)\rho_i$ , for  $i = 0, \dots, m-1$ <sup>99</sup>  $(6b)$  100

min

$$
\rho_0 = \rho_0^{img}.
$$
 (6c)  $\frac{^{101}}{^{102}}$ 

In equation  $(6a)$ ,  $\otimes$  is the Kronecker tensor product;  $\odot$  is the Hadamard product;  $I_k$  is the *k*-dimensional identity matrix;  $\|\cdot\|$  is the  $L^2$  norm of a vector. Equation [\(6b\)](#page-4-2) numerically solves the unbalanced advection-diffusion

<span id="page-4-2"></span><span id="page-4-1"></span>

**6 AUTHOR ONE ET ALL** rights reserved. No reuse allowed without permission. AUTHOR ONE ET ALL perpetuity. preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in medRxiv preprint doi: [https://doi.org/10.1101/2024.11.05.24316768;](https://doi.org/10.1101/2024.11.05.24316768) this version posted November 7, 2024. The copyright holder for this

<span id="page-5-0"></span>

equation [\(5b\)](#page-4-3) where an operator-splitting method is employed. Here,  $S(v_i)$  is the averaging matrix in the advection step to redistribute mass according to  $v_i$ ; L is the matrix for the diffusion operator; and  $R(r_i)$  is the matrix for the mass gain and loss step.

To numerically solve the discrete problem [\(6\)](#page-4-4), we use a Gauss-Newton iterative algorithm. See the pseudocode in Algorithm [1.](#page-5-0) We run Algorithm [1](#page-5-0) repeatedly between each pair of adjacent acquired DCE-MRI images to derive a series of prolonged velocity fields and relativesources. Specifically, for each DCE-MRI study consisting of *q* images  $\rho_0^{img}, \dots, \rho_{q-1}^{img}$ , the urOMT algorithm gives the optimal velocity fields  $v_{0,1}, \cdots, v_{q-2,q-1}$  and relativesources  $r_{0,1}, \cdots, r_{q-2,q-1}$ , where  $v_{i-1,i}$  denotes the velocity and *ri*−1*,i* denotes the relative-source transforming  $\rho_{i-1}^{img}$  into  $\rho_i^{img}$  for  $i = 0, \dots, q-2$ .

#### **2.3 The Eulerian and Lagrangian Post-processing**

With the model outputs, we then develop two postprocessing methods, the Eulerian and the Lagrangian post-processing, to reveal and visualize the properties of the fluid behaviors in tumors. The difference between the two methods lies in the coordinate an observer chooses to observe the dynamic system.

The Eulerian method employs a fixed coordinate with which we can extract quantitative metrics as defined in Table [1](#page-6-0) to reflect the local fluid properties. For example, Péclet is a dimensionless number to reflect the relative intensity of advection over diffusion. These metrics can be computed between each pair of adjacent image frames, and by connecting them together we have the corresponding time-varying metrics over all  $q - 1$ iterations.

In contrast, the Lagrangian method employs a floating coordinate which enables us to track the trajectories of the cross-voxel flows contributed by net advection and diffusion from a seed point over time, which we name 57 as the *pathlines*. Transport properties such as speed can 58 also be computed along the pathlines to derive what we 59 call the *speedlines*. By connecting the starting and ter-60 minal points of the pathlines, we derive the *displacement* 61 *field* and these vectors may be used to visualize the direc-62 tion and the distance a seed point has travelled in a 63 neat manner. The metrics extracted from the Lagrangian 64 post-processing method are summerized in Table [2](#page-6-1) . 55  $65$ 

More details can be found in Ref.  $[41, 46]$  $[41, 46]$  $[41, 46]$  about the 66 post-processing methods.

#### **2.4 Implementation Pipeline**

Here we describe implementation of the entire analysis process in this study.

For each DCE-MRI study, we first manually segmented the tumor region and dilated the tumor region by 2 voxels (about  $2 \text{ mm} \times 2 \text{ mm} \times 2.8 \text{ mm}$ ) to include some surrounding tissues as the region of interest (Figure [3](#page-7-0) a). Instead of processing all MRI images in the DCE-MRI experiment, we started at the 5th image frame (approximately 30 s after contrast injection) and proceeded to the end of DCE-MRI acquisition skipping every other image frames, i.e., 5th  $\rightarrow$  7th  $\rightarrow$  …, resulting in 12∼14 temporal 3D images to be analyzed. Starting with the 5th image provides a clear and stable signal. We then converted MRI signal intensity image within the ROI into contrast concentration image following equations [\(4a\)](#page-4-5) -  $(4d)$  (Figure [3](#page-7-0) b). Next, a 3D affine denoising filter <sup>[60](#page-13-18)</sup> which preserves edges was used to smooth the concentration images within the ROI (Figure [3](#page-7-0) c). The resulted smoothed series of volumetric data was processed by the urOMT algorithm<sup>[61](#page-13-19)</sup> with  $\sigma = 0.002$  (in numerical grid),  $\beta = 1000$  and  $\alpha = 30000$  to obtain model outputs (Figure [3](#page-7-0) d). Two post-processing methods were utilized to (i) generate temporal quantitative metrics detailed in Table [1](#page-6-0) and (ii) track the trajectories of the cross-voxel contrast agent movement over the analyzed time window whose metrics are detailed in Table [2](#page-6-1) (Figure [3](#page-7-0) e).

#### **2.5 Statistical Analysis**

In the Eulerian post-processing, we used two-sample *t*-test assuming unequal variances to evaluate the difference between pCR and non-pCR patients.

42 43

45

47

49

51 52 53 102 103 104

105 106

94

98

100 101

70

72 73 74

78

<span id="page-6-0"></span>**TABLE 1** Quantitative metrics extracted from the Eulerian post-processing method.



*<sup>a</sup>*mm is short for millimeter, mmol is short for millimole, and L stands for liter.

<span id="page-6-1"></span>**TABLE 2** Metrics from tracking cross-voxel transport using the Lagrangian post-processing method.



#### 3 RESULTS

07

10 11

15

17 18

21

23

25

27 28 29

32

37 38

45

47

49

51

53

## **3.1 urOMT Generates Dynamic Transport Metrics and Shows the Directional Trend of Fluid Flows**

For illustration, we show detailed results for one representative non-pCR breast cancer patient at the baseline (V1) in Figure [4](#page-8-0) . The dynamic metrics illustrate the changes of the tumor fluid properties over the analyzed time window which lasted about 7 minutes (Figure [4](#page-8-0) b). The times shown in Figure [4](#page-8-0) b indicate the approximate number of seconds from the start of DCE-MRI acquisition. For this particular study, contrast agent injection at 2 mL/s was initiated approximately 80 s after the start of DCE-MRI acquisition. Speed was very high in the first two to three DCE frames that were analyzed by the urOMT algorithm, which was rapidly decreased in the later frames. For the flux and Péclet metrics, it is clear that the flows in the tumor were stronger and

more advection-dominated near the ring-shaped boundary than the central region of the tumor. Influx was intense at first (colored dark red), indicating that the contrast agent was actively entering the tumor tissue. In 89 later frames, efflux increases (colored light blue), indicating a slow drainage of the contrast agent from the tumor tissue to the lymphatics and venous blood flow. The Lagrangian results display cross-voxel trajectories of the contrast agent. In Figure [4](#page-8-0) c-d, the pathlines and its corresponding displacement field indicate that the contrast agent flow primarily began as influx in a ring-shaped bordered region and mostly moved inwards to the center of the tumor. From the speed-lines, we can observe that speed of the flow was higher in the boundary than in the center of the tumor (Figure  $4 \text{ } e$  $4 \text{ } e$ ). From these results, we infer that in this case the tumor boundary was much more well-vascularized and that the center of the tumor was more diffusion-dominated and less active, indicating poor microvascularization or necrosis. 86 87 88 90 92 93 94 96 98 100 101 102 103

In Figure [5](#page-9-0) , the Lagrangian results of another non-pCR patient at baseline (V1) are shown. In some 105 106

55

61

 $65$ 

70

72 73 74

78

**8 AUTHOR ONE ET ALL** rights reserved. No reuse allowed without permission. AUTHOR ONE ET ALL perpetuity. preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in medRxiv preprint doi: [https://doi.org/10.1101/2024.11.05.24316768;](https://doi.org/10.1101/2024.11.05.24316768) this version posted November 7, 2024. The copyright holder for this

<span id="page-7-0"></span>

**FIGURE 3** The urOMT analysis pipeline. The green represents pre-processing; blue represents the main algorithm; yellow represents post-processing. **a**. DCE-MRI images were first segmented by radiologists to derive the tumor contour which was further dilated by about 2 mm as the region of interest (ROI). **b**. DCE-MRI signal images within the ROI were converted into concentration  $C(t)$  images of contrast agent. **c**. The images within the ROI were further smoothed with a denoising filter to remove image noise. **d**. Pre-processed concentration images were then used as inputs for the urOMT model. **e**. Model outputs were post-processed to extract the temporal metrics listed in Table [1](#page-6-0) and to track the trajectories of cross-voxel transport whose metrics are listed in Table [2](#page-6-1) .

locations the fluid flow converged and at other locations diverged. Moreover, the speed was also unevenly distributed inside of the tumor. It seems likely that the tumor vasculature was robust in some regions (the yellow solid boxes) but mostly inactive in others (white dashed boxes) (Figure [5](#page-9-0) b). A 3D-rendering video of the results can be found at [Github.](https://github.com/xinan-nancy-chen/urOMT/blob/main/BC36_01_urOMT_LagResults_compressed.mp4)

### **3.2 urOMT-derived metrics as potential biomarkers of therapeutic response**

10

15

17 18

27

31 32

37 38

45

47

49 50 51

53

Next, we computed the temporal average of flux, influx and efflux for all MRI visits. We observed that for the pCR patients the average flux, influx and efflux were all decreased compared to the baseline (V1), presumably due to the impact of NACT on the microvasculature. In contrast, the non-pCR patients seemed to be more likely to experience an increase in some metrics during NACT (at V2, V3 and V4). Figure [6](#page-10-0) shows longitudinal changes of the time-averaged metrics for one pCR and one non-pCR patient. For the pCR patient, in addition to the shrinkage of the tumor, all the metric values decreased at the three visits (V2, V3 and V4) after NACT initiation compared to baseline (V1). However, for the non-pCR patient, there was a substantial elevation of flux and efflux at V3 and V4, although at V2

the metrics were slightly decreased compared to baseline. This suggests possible tumor resistance to NACT after a moderate initial response to the first NACT cycle.

For all 39 patients, we calculated the temporal and spatial averages of flux, influx and efflux for all 153 DCE-MRI scans and computed their percentage change from baseline (V1). To be specific, for  $V1 \rightarrow Vi$ , percentage change from baseline of a metric *M* is

$$
(M_i - M_1)/M_1 \tag{7}
$$

54 55

 $65$ 

70

78

where  $M_i$  is the metric at V*i*. In this dataset, there are 3 patients whose V3 data are missing. These patients' data were still included in the analysis for completeness, and we used the interpolated metric values at V2 and V4 as their estimated V3 metric values. There is one patient whose V3 and V4 were identified by radiologists as complete imaging response, thus no ROI was provided, for which we set their metrics to zero at V3 and V4. In Figure [7](#page-10-1) , we longitudinally plotted the percentage changes from baseline of average flux, influx, and efflux for all 39 patients. Note that flux at V3 was decreased to larger extent for pCR (-47.26%) than for non-pCR patients  $(2.28\%, p = 0.0042)$ . Flux was also lower at V4 in pCR (-51.70%) vs. non-pCR patients  $(-8.59\%, p = 0.0111)$ . Influx was reduced at V4 in pCR  $(-8.59\% , p = 0.0111)$ . 56.32%) than in non-pCR  $(-21.56\%, p = 0.0473)$ . Lastly, efflux was decreased more at V4 in pCR (-79.07%) than 89 90 91 92 94 96 97 98 100 101 102 103 105 106

<span id="page-8-0"></span>medRxiv preprint doi: [https://doi.org/10.1101/2024.11.05.24316768;](https://doi.org/10.1101/2024.11.05.24316768) this version posted November 7, 2024. The copyright holder for thispreprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. AUTHOR ONE ET AL **ALL CONET ALCONG ALL REGISTER** PERPENITY.<br>All rights reserved. No reuse allowed without permission. speed-lines a C pathlines d displacement field ė **ROI** tumor  $\mathfrak{o}$ start magnitude  $8.5 \text{ mm}$  $\overline{0}$ speed  $3.5$  mm/min end (contrast agent<br>concentration) b 100s  $300s$  $340s$ 380s 500s 540s  $140<sub>s</sub>$  $180<sub>s</sub>$  $220s$ 260s  $420s$ 460s  $0.53$ inputs  $3.5$ speed ہ ا  $0.23$ flux l o 400 Péclet  $\overline{0}$  $0.16$ influx mm<br>0 efflux  $-0.16$ mmol/(L-min)

**FIGURE 4** Results from a representative non-pCR patient at baseline (V1). **a**. 3D rendered post-contrast MRI image with the ROI of the tumor region color-coded in orange. **b**. Input contrast concentration images in the tumor ROI (first row) and dynamic results of quantitative metrics from the Eulerian post-processing (bottom four rows). The times shown in the first row are approximate number of seconds after the start of DCE-MRI acquisition. The images are shown at the same centered slice in 2D. **c-e**. Tracked cross-voxel flows over the analyzed time window from Lagrangian post-processing. The results are overlaid on a gray-scale concentration image and are shown in projection from the middle 5 slices of the tumor.

in non-pCR  $(-2.58\%, p = 0.0189)$ . Table [3](#page-9-1) summarizes the the longitudinal percent change of the metrics values.

10

15

17

23

25

27

31 32

37 38

46 47

53

These observations suggested that although NACT reduced microvascular fluid transport in the breast tumors, the timing and extent of the effect were different between the pCRs and non-pCRs. If we simply identify patients whose average flux, influx and efflux were all decreased from V1 to all three follow-up visits as *urOMT-response-positive* and pCR as pathology testpositive, we have the following confusion matrix comparing predictions by urOMT with pathologic response outcomes:



By this definition, the accuracy of this simple response classifier was 77%. And the corresponding sensitivity and specificity are 75% and 77%, respectively.

#### 4 DISCUSSION

Commonly used quantitative DCE-MRI data analysis 85 approaches, for example, the Tofts-type methods  $25,26$  $25,26$ only allow for contrast influx and efflux, measured by  $\frac{87}{100}$ biomarkers  $K^{trans}$  and  $k_{ep}$  to reflect volume transfer rate 88 constants of the contrast agent for the passive transport 89 mechanisms from the local arterial supply to tissue interstitial space and back into the draining venous vessels, 91 respectively. However, their lack of considering cross-92 voxel flows characterized by advection and diffusion 93 may lead to bias of the modeled results. For instance, 94 Fluckiger et al. studied the effects of contrast molecule 95 diffusion on the analysis of DCE-MRI data in realistic 96 tissue domains and suggested incorporating a correc-97 tion for the slow diffusion of the contrast agent.  $62 \text{ In a}$  $62 \text{ In a}$  s recent study, Sinno et al. developed a modified Toftsbased approach for DCE-MRI analysis that explicitly 100 models cross-voxel flows and demonstrated that ETM 101 underestimates the effects of cross-voxel exchange. [63](#page-13-21) 86 102

In contrast, in addition to quantifying temporally 103 and spatially resolved influx and efflux, the urOMT model can capture net directional bulk flows within 105

55

 $65$ 

70

72



<span id="page-9-0"></span>

**FIGURE 5** Heterogeneity of fluid flows can be visualized by the Lagrangian post-processing method. **a**. 3D rendered post-contrast MRI image of the tumor from a non-pCR patient at baseline (V1) with the ROI region color-coded in orange. **b**. Corresponding 3D rendered Lagrangian results (pathlines, displacement field and speed-lines) when the tumor is cross-sectioned by the central sagittal plane (top row) and the central axial plane (bottom row). The yellow solid boxes are where the tumor flow was the most active and the white dashed boxes are where the tumor flow was the most inactive.

		$pCR(N=8)$		non-pCR $(N = 31)$		
<b>Metrics</b>	Visit	mean	<b>STD</b>	mean	<b>STD</b>	$p$ -value
flux	$V1 \rightarrow V2$	$-0.2140$	0.1762	0.0243	0.5624	0.0523
	$V1 \rightarrow V3$	$-0.4726$	0.3049	0.0228	0.6341	$0.0042**$
	$V1 \rightarrow V4$	$-0.5170$	0.3251	$-0.0859$	0.5680	$0.0111*$
influx	$V1 \rightarrow V2$	$-0.1842$	0.3395	0.0822	0.7144	0.1422
	$VI \rightarrow V3$	$-0.4585$	0.3437	$-0.1452$	0.5736	0.0645
	$V1 \rightarrow V4$	$-0.5632$	0.3433	$-0.2156$	0.6200	$0.0473*$
efflux	$V1 \rightarrow V2$	$-0.2648$	0.7539	0.5034	1.8672	0.0832
	$V1 \rightarrow V3$	$-0.6038$	0.5328	$-0.1086$	1.0626	0.0777
	$V1 \rightarrow V4$	$-0.7907$	0.3666	$-0.0258$	1.5778	$0.0189*$

<span id="page-9-1"></span>**TABLE 3** Percent change from baseline of urOMT-derived metrics across all 39 patients at V2, V3 and V3.

<sup>∗</sup> *p <* 0*.*05, ∗∗*p <* 0*.*005. A two-sample *t*-test assuming unequal variances was used to assess difference between the pCR and non-pCR group.

the tumor volume. This is achieved via smooth continuous cross-voxel transport modeled by a combination of advection and diffusion. urOMT thus incorporates four transport motions under two categories, i.e., tumor blood supply (influx and efflux) and cross-voxel transport (advection and diffusion), to provide a more

10

15

17 18

23 24 25

27

32

34

38 39 40

47 48 49

51

53

complete blood transport framework. Furthermore, the 101 urOMT model enforces a continuity in space and time. 102 Specifically, it can characterize the transport system by  $103$ returning time-dependent dynamic metrics rather than 104 time-independent constant metrics such as *Ktrans* of 105 Tofts-type models. This captures the changing behavior 106

77 78 79

97 98

<span id="page-10-0"></span>

**FIGURE 6** Comparison of temporal averages of quantitative flow metrics of one pCR patient (left) and one non-pCR patient (right) at four DCE-MRI visits before, during, and after NACT treatment. The first column is the last frame DCE-MRI images, while the other three columns are color parametric maps of the urOMT-derived metrics overlaid on the MR images.

<span id="page-10-1"></span>

**FIGURE 7** Percentage changes from baseline (V1) of average flux (**a**), average influx (**b**) and average efflux (**c**) for all 39 patients at V2, V3, and V4. Detailed statistics are listed in Table [3](#page-9-1) . A two-sample *t*-test assuming unequal variances was used to assess difference between the pCR and non-pCR group.  $^*p < 0.05$ ,  $^{**}p < 0.005$ .

of contrast agent flow as it moves from an arterial supply phase to a venous/lymphatic removal phase. Finally, the urOMT model can track and visualize net trajectories of cross-voxel contrast transport over the analyzed time window, thus quantifying directional information on the fluid transport. To the best of our knowledge, this is the first model that traces detailed contrast flow patterns within a tumor.

 

 

In this preliminary study, we applied a mathematical model in computational fluid dynamics, called the urOMT model, to analyze longitudinal DCE-MRI data from breast cancer patients treated with NACT. As demonstrated by the initial results from 153 DCE-MRI data sets from 39 breast cancer patients, the urOMT-derived metrics have the potential to serve as imaging biomarkers to quantify and predict therapeutic 106 

responses. The applicability of urOMT is not limited to breast cancer, and could be applied to a wide variety of DCE-MRI studies of various cancer types.

The current urOMT model, however, is not without limitations. In particular, the model currently assumes that diffusion is constant across the tumor. This is certainly not strictly true, although in many cases diffusion may be a minor component of transport. This constraint could be relaxed in future versions. Besides, establishing the urOMT-derived metrics as robust biomarkers for cancer therapy response will require larger datasets for validation.

## ACKNOWLEDGMENTS

01

04

07 08

21

23 24 25

27

31

34

37

43

45

47

51

This study was supported by the NIH Cancer Center Support grant to MSK (P30 CA008748), NIH grant U01 CA154602, R01 CA248192, The Enid A. Haupt Endowed Chair Fund for Medical Physics, The Simons Foundation, and a Breast Cancer Research Foundation grant (BCRF-17-193).

We gratefully acknowledge Dr. Allen Robert Tannenbaum, whose mentorship and contributions have profoundly shaped this research. Dr. Tannenbaum sadly passed away before the completion of this work.

## **4.1 Author contributions**

The project was conceived by X. C., W. H., and J. O. D. The theory, numerical method, code development of urOMT were done by X. C. The DCE-MRI data collection and processing were performed by W. H., A. S. D., and R. P. Tumor segmentation was performed by R. L. G., M. P. and K. P. The data interpretation was contributed by A. S. D., R. P., K. P. and J. O. D. The first draft of the manuscript was written by X. C. and all authors commented on previous versions of the manuscript. All authors read and approved the final manuscript.

## **4.2 Financial disclosure**

Nothing to disclose.

## **4.3 Conflict of interest**

The authors declare no potential conflict of interests.

## DATA AVAILABILITY STATEMENT

The code for the urOMT method can be found at Github [\(https://github.com/xinan-nancy-chen/urOMT\)](https://github.com/xinan-nancy-chen/urOMT) or at 57 Zenodo. $61$  The DCE-MRI data is taken from the study  $58$ published by [\[56\]](#page-13-14). Data availability is limited due to 59 privacy concerns and consent form limitations. 56

55

61

70

## ORCID

*Xinan Chen* **0** <0000-0002-2418-5041> *Roberto Lo Gullo* **<0000-0001-6887-292X>** *Katja Pinker* **1** <0000-0002-2722-7331> *Joseph O. Deasy* **<0000-0002-9437-266X>** 

## REFERENCES

- <span id="page-11-0"></span>1. Charfare H, Limongelli S, Purushotham AD. Neoadjuvant chemotherapy in breast cancer. *Journal of British Surgery.* 2005;92(1):14–23. 72 73
- <span id="page-11-1"></span>2. Asaoka Mariko, Gandhi Shipra, Ishikawa Takashi, Takabe Kazuaki. Neoadjuvant chemotherapy for breast cancer: past, present, and future. *Breast cancer: basic and clinical research.* 2020;14:1178223420980377. 74 75
- <span id="page-11-2"></span>3. Antonini Marcelo, Mattar André, Richter Fernanda Grace Bauk, et al. Real-world evidence of neoadjuvant chemotherapy for breast cancer treatment in a Brazilian multicenter cohort: Correlation of pathological complete response with overall survival. *The Breast.* 2023;72:103577. 78 80
- <span id="page-11-3"></span>4. An Selena J, Duchesneau Emilie D, Strassle Paula D, et al. Pathologic complete response and survival after neoadjuvant chemotherapy in cT1-T2/N0 HER2+ breast cancer. *NPJ Breast Cancer.* 2022;8(1):65. 82 83 84 85
- <span id="page-11-4"></span>5. Mann Ritse M, Kuhl Christiane K, Moy Linda. Contrastenhanced MRI for breast cancer screening. *Journal of Magnetic Resonance Imaging.* 2019;50(2):377–390. 86 87
- <span id="page-11-5"></span>6. Leithner D, Wengert GJ, Helbich TH, et al. Clinical role of breast MRI now and going forward. *Clinical radiology.* 2018;73(8):700–714. 88 89
- <span id="page-11-6"></span>7. Türkbey Bariş, Thomasson David, Pang Yuxi, Bernardo Marcelino, Choyke Peter L. The role of dynamic contrastenhanced MRI in cancer diagnosis and treatment. *Diagnostic and interventional radiology (Ankara, Turkey).* 2010;16(3):186. 91 92 94
- <span id="page-11-7"></span>8. Udayakumar Durga, Madhuranthakam Ananth J, Doğan Ba¸sak E. Magnetic Resonance Perfusion Imaging for Breast Cancer. *Magnetic Resonance Imaging Clinics.* 2024;32(1):135–150. 96 97 98
- <span id="page-11-8"></span>9. Lee Jeongmin, Kim Sung Hun, Kang Bong Joo. Pretreatment prediction of pathologic complete response to neoadjuvant chemotherapy in breast cancer: Perfusion metrics of dynamic contrast enhanced MRI. *Scientific Reports.* 2018;8(1):9490. 100
- <span id="page-11-9"></span>10. Choyke Peter L, Dwyer Andrew J, Knopp Michael V. Functional tumor imaging with dynamic contrast-enhanced magnetic resonance imaging. *Journal of Magnetic Resonance Imaging: An Official Journal of the International Society for* 106 104 105

preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in medRxiv preprint doi: [https://doi.org/10.1101/2024.11.05.24316768;](https://doi.org/10.1101/2024.11.05.24316768) this version posted November 7, 2024. The copyright holder for this

*Magnetic Resonance in Medicine.* 2003;17(5):509–520.

- <span id="page-12-0"></span>11. Schaaf Marco B, Garg Abhishek D, Agostinis Patrizia. Defining the role of the tumor vasculature in antitumor immunity and immunotherapy. *Cell death & disease.* 2018;9(2):115.
- <span id="page-12-1"></span>12. Wagner Marek, Wiig Helge. Tumor interstitial fluid formation, characterization, and clinical implications. *Frontiers in oncology.* 2015;5:115.
- <span id="page-12-2"></span>13. Bekisz Sophie, Baudin Louis, Buntinx Florence, Noël Agnès, Geris Liesbet. In vitro, in vivo, and in silico models of lymphangiogenesis in solid malignancies. *Cancers.* 2022;14(6):1525.
- <span id="page-12-3"></span>14. Stewart Randolph H. A modern view of the interstitial space in health and disease. *Frontiers in Veterinary Science.* 2020;7:609583.
- <span id="page-12-4"></span>15. Jackson Alan, Li Ka-Loh, Zhu Xiaoping. Semi-quantitative parameter analysis of DCE-MRI revisited: Monte-Carlo simulation, clinical comparisons, and clinical validation of measurement errors in patients with type 2 neurofibromatosis. *PloS one.* 2014;9(3):e90300.
- <span id="page-12-5"></span>16. Huang Wei, Li Xin, Morris Elizabeth A, et al. The magnetic resonance shutter speed discriminates vascular properties of malignant and benign breast tumors in vivo. *Proceedings of the National Academy of Sciences.* 2008;105(46):17943– 17948.
- <span id="page-12-6"></span>17. Li Xia, Welch E Brian, Chakravarthy A Bapsi, et al. Statistical comparison of dynamic contrast-enhanced MRI pharmacokinetic models in human breast cancer. *Magnetic resonance in medicine.* 2012;68(1):261–271.
- <span id="page-12-7"></span>18. LoCastro Eve, Paudyal Ramesh, Konar Amaresha Shridhar, et al. A Quantitative Multiparametric MRI Analysis Platform for Estimation of Robust Imaging Biomarkers in Clinical Oncology. *Tomography.* 2023;9(6):2052–2066.
- <span id="page-12-8"></span>19. Shalom Eve S, Kim Harrison, Der Heijden Rianne A, et al. The ISMRM Open Science Initiative for Perfusion Imaging (OSIPI): Results from the OSIPI–Dynamic Contrast-Enhanced challenge. *Magnetic resonance in medicine.* 2024;91(5):1803–1821.
- <span id="page-12-9"></span>20. Woolf David K, Taylor N Jane, Makris Andreas, et al. Arterial input functions in dynamic contrast-enhanced magnetic resonance imaging: which model performs best when assessing breast cancer response?. *The British journal of radiology.* 2016;89(1063):20150961.
- <span id="page-12-10"></span>21. Li Xia, Arlinghaus Lori R, Ayers Gregory D, et al. DCE-MRI analysis methods for predicting the response of breast cancer to neoadjuvant chemotherapy: Pilot study findings. *Magnetic resonance in medicine.* 2014;71(4):1592–1602.
- <span id="page-12-11"></span>22. Ramtohul Toulsie, Tescher Clara, Vaflard Pauline, et al. Prospective evaluation of ultrafast breast MRI for predicting pathologic response after neoadjuvant therapies. *Radiology.* 2022;305(3):565–574.
- <span id="page-12-12"></span>23. Thawani Rajat, Gao Lina, Mohinani Ajay, et al. Quantitative DCE-MRI prediction of breast cancer recurrence following neoadjuvant chemotherapy: a preliminary study. *BMC Medical Imaging.* 2022;22(1):182.
- <span id="page-12-13"></span>24. Liang Xinhong, Chen Xiaofeng, Yang Zhiqi, et al. Early prediction of pathological complete response to neoadjuvant chemotherapy combining DCE-MRI and apparent diffusion coefficient values in breast Cancer. *BMC cancer.* 2022;22(1):1250.
- <span id="page-12-14"></span>25. Tofts Paul S. Modeling tracer kinetics in dynamic Gd-DTPA MR imaging. *Journal of magnetic resonance imaging.* 1997;7(1):91–101. 54
- <span id="page-12-15"></span>26. Tofts Paul S, Brix Gunnar, Buckley David L, et al. Estimating kinetic parameters from dynamic contrast-enhanced T1-weighted MRI of a diffusable tracer: standardized quantities and symbols. *Journal of Magnetic Resonance Imaging: An Official Journal of the International Society for Magnetic Resonance in Medicine.* 1999;10(3):223–232. 58
- <span id="page-12-16"></span>27. Monge Gaspard. Mémoire sur la théorie des déblais et des remblais. *Mem. Math. Phys. Acad. Royale Sci..* 1781;:666– 704.  $62$
- <span id="page-12-17"></span>28. Villani Cédric. *Topics in Optimal Transportation*. American Mathematical Soc.; 2003.
- <span id="page-12-18"></span>29. Benamou Jean-David, Brenier Yann. A computational fluid mechanics solution to the Monge-Kantorovich mass transfer problem. *Numerische Mathematik.* 2000;84(3):375–393. 68
- <span id="page-12-19"></span>30. Cuturi Marco. Sinkhorn distances: Lightspeed computation of optimal transport. *Advances in neural information processing systems.* 2013;26.  $69$
- <span id="page-12-20"></span>31. Benamou Jean-David, Carlier Guillaume, Cuturi Marco, Nenna Luca, Peyré Gabriel. Iterative Bregman projections for regularized transportation problems. *SIAM Journal on Scientific Computing.* 2015;37(2):A1111–A1138. 72 74
- <span id="page-12-21"></span>32. Chen Yongxin, Georgiou Tryphon T, Pavon Michele. On the relation between optimal transport and Schrödinger bridges: A stochastic control viewpoint. *Journal of Optimization Theory and Applications.* 2016;169(2):671–691. 75 78
- <span id="page-12-22"></span>33. Léonard Christian. From the Schrödinger problem to the Monge–Kantorovich problem. *Journal of Functional Analysis.* 2012;262(4):1879–1920.
- <span id="page-12-23"></span>34. Khamis Abdelwahed, Tsuchida Russell, Tarek Mohamed, Rolland Vivien, Petersson Lars. Scalable Optimal Transport Methods in Machine Learning: A Contemporary Survey. *IEEE Transactions on Pattern Analysis and Machine Intelligence.* 2024;. 82 83 84 85
- <span id="page-12-24"></span>35. Wang Yue, Sun Yongbin, Liu Ziwei, Sarma Sanjay E, Bronstein Michael M, Solomon Justin M. Dynamic graph cnn for learning on point clouds. *ACM Transactions on Graphics (tog).* 2019;38(5):1–12. 86 87 88
- <span id="page-12-25"></span>36. Sarlin Paul-Edouard, DeTone Daniel, Malisiewicz Tomasz, Rabinovich Andrew. Superglue: Learning feature matching with graph neural networks. In: :4938–4947; 2020. 89 91
- <span id="page-12-26"></span>37. Balaji Yogesh, Chellappa Rama, Feizi Soheil. Robust optimal transport with applications in generative modeling and domain adaptation. *Advances in Neural Information Processing Systems.* 2020;33:12934–12944. 92
- <span id="page-12-27"></span>38. Moriel Noa, Senel Enes, Friedman Nir, Rajewsky Nikolaus, Karaiskos Nikos, Nitzan Mor. NovoSpaRc: flexible spatial reconstruction of single-cell gene expression with optimal transport. *Nature protocols.* 2021;16(9):4177–4200. 96 97 98
- <span id="page-12-28"></span>39. Cang Zixuan, Zhao Yanxiang, Almet Axel A, et al. Screening cell–cell communication in spatial transcriptomics via collective optimal transport. *Nature methods.* 2023;20(2):218–228.
- <span id="page-12-29"></span>40. Elkin Rena, Nadeem Saad, Haber Eldad, et al. GlymphVIS: visualizing glymphatic transport pathways using regularized optimal transport. In: :844–852Springer; 2018. 103
- <span id="page-12-30"></span>41. Koundal Sunil, others . Optimal Mass Transport with Lagrangian Workflow Reveals Advective and Diffusion 104

53

01

07 08

17 18

21

23 24

27

31 32

37 38

41 42 43

45

47 48

<span id="page-13-15"></span><span id="page-13-14"></span><span id="page-13-13"></span><span id="page-13-12"></span><span id="page-13-11"></span><span id="page-13-10"></span><span id="page-13-9"></span><span id="page-13-8"></span><span id="page-13-7"></span><span id="page-13-6"></span><span id="page-13-5"></span><span id="page-13-4"></span><span id="page-13-3"></span><span id="page-13-2"></span><span id="page-13-1"></span><span id="page-13-0"></span>

<span id="page-13-21"></span><span id="page-13-20"></span><span id="page-13-19"></span><span id="page-13-18"></span><span id="page-13-17"></span><span id="page-13-16"></span>preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in medRxiv preprint doi: [https://doi.org/10.1101/2024.11.05.24316768;](https://doi.org/10.1101/2024.11.05.24316768) this version posted November 7, 2024. The copyright holder for this